Patient21, a direct primary care provider, has successfully raised EUR 100 million (USD 108 million) in a Series C funding round. The funds raised were a combination of debt (~30%) and equity (~70%). Pitango led the equity funding, with participation from other venture capital firms and angel investors, while IPF Partners provided the debt portion. This latest round brings the company's total funding to EUR 174 million (USD 188 million).

The funds will be used to expand the company's software offerings and broaden its geographical reach beyond its current presence in Germany. The company has outlined its plans to enter two new European markets within the next twelve months. Patient21 plans to launch 10–15 dental clinics in the new markets, in addition to establishing 40–50 new clinics within Germany over the next 12 months. The funds will also be allocated toward developing a generative AI tool designed for diagnostics using X-rays.

Furthermore, in the long term, Patient21 intends to license its booking and patient-management software to other entities. The company aims to sell its software platform to other clinics as a white-label solution, commencing in 2024.

Germany-based Patient2 offers patient and practice management software solutions, alongside operating multiple physical health clinics. While its primary focus lies in digital patient management, Patient21 also directs patients to one of its 50+ clinics spread across Germany for treatment. Currently, the company's emphasis is predominantly on dentistry, with the remaining clinics divided between gynecology and primary care practices. Overall, the company records 300,000 patient visits annually.